Drugs /

rptr-147

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for rptr-147

Rptr-147 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating rptr-147, 1 is phase 1 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for rptr-147 clinical trials.

Clear cell renal cell carcinoma, head and neck squamous cell carcinoma, and lymphoma are the most common diseases being investigated in rptr-147 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rptr-147
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rptr-147 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
rptr147, rptr 147, prime il-15

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.